Dealmaking Quarterly Statistics, Q4 2022
A Look At M&A And Alliance Activity Across The Biopharma, Medical Device And In Vitro Diagnostics Industries, October-December 2022
During Q4, biopharma merger and acquisition value reached $35.7bn and drew in $62.1bn in potential deal value from alliances. Device company M&A values reached $19.2bn, while in vitro diagnostic firms and research tools players completed M&A activity that totaled $4.8bn.
You may also be interested in...
Ten $1bn+ alliances were penned in January. In the top alliance by deal value, Shanghai Argo Biopharmaceutical entered into exclusive collaboration with Novartis Pharma for two undisclosed Argo cardiovascular disease programs, one in Phase I and another in Phase I/IIa. Novartis gets an exclusive global license to develop and commercialize the Phase I program and also receives an option to potentially license compounds directed against up to two additional targets. For the Phase I/IIa program, Novartis gets an exclusive license worldwide except in Greater China. The deal could be worth up to $4.17bn for Argo.
During Q4, biopharma merger and acquisition deal value reached $63bn and drew in $75.4bn in potential deal value from alliances. Device company M&A values reached $4.8bn, while in vitro diagnostics and research tools players’ M&A activity totaled $3.4bn.
During the fourth quarter, biopharmas brought in an aggregate $13.1bn in financing and device company fundraising totaled $1.1bn; while in vitro diagnostic firms and research tools players raised $459m.